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Watson and Ogilvie scores and with the dysphagia mod-
ule in the QoL scale (QLQ-OG25). On average, there was 
a tendency to better dysphagia relief for the fully-covered 
design as scored with the two latter dysphagia instruments 
(p= 0.081 and p= 0.067) at three months and towards more 
re-interventions in the semi-covered group (p= 0.083).
Conclusion In spite of its somewhat lower intrinsic radial 
force, the fully-covered stent was comparable to the con-
ventional semi-covered stent with regard to stent migration. 
The data further suggest a potential benefit of the fully-cov-
ered stent in improving dysphagia in patients with longer 
life expectancy.
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The incidence of cancers of the esophagus and gastro-
esophageal junction (GEJ) is rising in the Western world 
[1]. The majority of patients are not eligible for cura-
tive treatment due to either an advanced tumor stage or 
a poor general condition [2, 3]. A very important goal is 
thus to provide optimized palliative care and to maintain 
or improve quality of life (QoL). Dysphagia is the most 
important symptom to relieve, since it affects QoL most 
negatively [3, 4]. In recent years endoscopically placed 
self-expandable metallic stents (SEMS) have become a 
well-documented, effective and widely used palliative treat-
ment for dysphagia, in particular among patients with a life 
expectancy of less than 3 months [4–7].
The first commercially available SEMS in the 1990s 
were uncovered and were associated with a re-intervention 
rate of up to 30–50%, most commonly due to stent obstruc-
tion secondary to tumor or inflammatory tissue in-growth 
[8, 9]. A variety of different SEMS designs equipped with 
Abstract 
Introduction Stent migration is a significant clinical prob-
lem in palliation of malignant strictures in the esophagus 
and gastro-esophageal junction (GEJ). We have compared a 
newer design of a fully-covered stent to a widely used semi-
covered stent using migration >20 mm as the primary out-
come variable. Effects on dysphagia, quality of life (QoL) 
and re-intervention frequency were also investigated.
Methods Patients with dysphagia due to non-curable 
esophagus/GEJ cancer were randomized to receive either a 
more recent design of a fully-covered stent (n = 48) or a 
conventional semi-covered stent (n = 47). Chest x-ray, dys-
phagia and QoL were studied at baseline, one week, four 
weeks and three months thereafter.
Results There were no significant differences either in 
stent migration distance or in the migration frequency. 
Stent migration during the total study period occurred in 
37.2 % in the semi-covered group compared to 20.0 % for 
the fully-covered group. Dysphagia was measured with 
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a plastic lining covering the exterior surface of the stent 
were subsequently developed to prevent this complication 
[10]. Unfortunately, whereas the smooth lining of the first 
generation of covered stents helped to prevent tumor in-
growth, those SEMS adhered less well to the esophageal 
wall. A common and acknowledged disadvantage of fully 
covered SEMS (fcSEMS) is therefore a high risk (20–39%) 
for stent dysfunction due to dislocation [11–15] leading to 
recurrent or insufficient relief of dysphagia. Semi-covered 
stents (scSEMS), i.e., covered in the mid portion but with 
bare mesh endings were developed; these cause less migra-
tion-related events although re-obstruction in the uncov-
ered endings may still occur [11, 16, 17]. Despite these 
limitations scSEMS are commonly used throughout the 
world. When this study was launched, the scSEMS were 
the most widely used stents for palliation of cancers of the 
esophagus and cardia in Sweden, in particular the Ultraflex 
stent, which therefore was chosen to this study. In recent 
years, newer designs of fcSEMS modified to reduce the 
risk of migration have been developed. The fcSEMS used 
in this study  (Wallflex®) differs from earlier generations of 
fcSEMS designs in several aspects. It has its silicone lining 
on the interior luminal side of the stent, which leaves the 
rough surface of the braided stent mesh facing the mucosa. 
These modifications, together with a different shape of the 
flare at the endings, are in theory thought to reduce stent 
migration. Another important factor to consider when stud-
ying stent migration is the inborn radial force of the stent. 
The fcSEMS  Wallflex® has a slightly lower radial force 
compared to the well-established scSEMS  Ultraflex® [18], 
which theoretically could entail a higher risk for migration. 
Whether the  Wallflex® fcSEMS is comparable to the con-
ventional  Ultraflex® scSEMS with regard to migration is 
not yet known.
Previous studies addressing the advantages or limita-
tions of different stent designs in palliation of cancers of 
the esophagus and cardia have focused on parameters such 
as QoL, dysphagia relief or need for endoscopic re-inter-
ventions due to perceived symptoms as the main outcome 
measures. However, there is little evidence available con-
cerning the degree of actual stent migration with regard 
to stent designs. To our knowledge, earlier investigations 
have consistently shown higher migration rates of fcSEMS 
regardless of the design [11–15]. In this study, we there-
fore tested the hypothesis that the most widely used con-
ventional scSEMS  (Ultraflex®) is associated with less stent 
migration compared to a more modern fcSEMS design 
 (Wallflex®). The primary endpoint of this prospective, ran-
domized study was to compare these stent designs with 
regard to migration over time using direct measurements in 
conventional chest X-ray images. The need for re-interven-
tions, effects on dysphagia and QoL, technical failures and 
survival were used as secondary endpoints.
Methods
Inclusion
Between 2011 and 2014, 95 patients with incurable can-
cer in the esophagus or the GEJ were asked to participate 
in this prospective randomized study. The patients were 
recruited from four university hospitals and two district 
hospitals. The demographic background characteristics of 
the groups are shown in Table 1. Before the endoscopy, the 
patients were randomized to receive either an fcSEMS or 
a scSEMS through a web-based computer-aided system 
(DynaReg Generic system). By minimization, the groups 
were stratified between a distal tumor margin of <3  cm, 
or >3  cm from the GEJ in order to avoid dissimilarities 
between the groups with regard to the level of the stricture.
The inclusion criteria were as follows: (1) Biopsy-ver-
ified squamous cell carcinoma or adenocarcinoma in the 
esophagus or the GEJ where stent-treatment is applicable; 
(2) Age >18 years; (3) swallowing difficulties with a sever-
ity of dysphagia of 2–4 according to Ogilvie [19]; (4) Cura-
tive treatment not possible; (5) Written informed consent 
obtained from the patient.
Table 1  Background 
characteristics of the patients 
included







Age year median (min–max) 72.2 (48.2–91.0) 71.2 (56.8–91.0) 0.5391
Gender (n = female) 11 (23.4%) 13 (27.1%) 0.6352
Distal margin from cardia <3 cm (n = yes) 33 (70.2%) 35 (72.9%) 0.6352
Tumor length (cm) median (min–max) 6.0 (1.0–18.0) 6.0 (1.0–14.0) 0.5761
Tumor type (n = adenocarcinoma) 32 (34.8%) 35 (38.0%) 0.1432
Metastatic disease (n = yes) 25 (53.2%) 29 (60.4%) 0.3672
Dilatation during stent procedure 2 (4.2%) 0 (0.0%) 0.1492
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The exclusion criteria were as follows: (1) Other concur-
rent malignancy that might impact the life span and/or QoL 
of the patient; (2) Inability to understand or complete the 
written questionnaire; (3) Need for a stent with the upper 
margin less than 2 cm from the upper esophageal sphincter; 
(4) Need of more than one stent to bridge the tumor.
Procedure
The patients were randomized to receive either a scSEMS 
 (Ultraflex® Esophageal NG Stent System Boston Scien-
tific) or an fcSEMS  (Wallflex® fully covered Esophageal 
stent Boston Scientific). The patients were not informed 
about which stent they received. The  Ultraflex® stent con-
sists of a knitted nickel-titanium alloy (Nitinol) wire tube 
and has a polyurethane layer, which covers the midsection 
of the stent extending to within 1.5 cm of either end of the 
stent (Fig. 1). The stent used in this study had a proximal 
flare of 23 mm and an inner body diameter of 18 mm. It 
was available in three lengths: 100, 120, and 150 mm. The 
 Wallflex® stent is made of a multiple-wired mesh of Nitinol 
and has a full silicone internal covering with progressive 
step-flared ends (Fig.  1). The body diameter of the stent 
used was 18 mm, and the flare diameters were 25 mm prox-
imally, and 23 mm distally. This stent was available in three 
lengths: 103, 123, and 153 mm. All available stent lengths 
were used in both groups.
The vast majority of patients undergoing the endo-
scopic procedure were treated under conscious sedation 
with midazolam, and alfentanil or pethidine in addition. 
The upper and when possible also the lower margin of the 
tumor was marked with a metal clip. If it was impossible 
to pass the tumor with the endoscope, the length of the 
obstruction was determined by the radiological findings or 
by the use of an “on the table” conventional contrast X-ray. 
Under fluoroscopic X-ray guidance, a guide-wire was 
passed down to the stomach. When the endoscope had been 
removed, the stent was inserted over the wire and posi-
tioned in relation to the clips. The length of the stent was 
chosen according to the length of the stricture, and the stent 
was placed with at least a 2 cm proximal and distal over-
lap to the upper and lower margins of the tumor. In cases 
where the stent was positioned with its distal end below 
the cardia, the distal overlap was aimed at 1 cm. Dilatation 
was not done routinely to be able to pass the tumor with the 
endoscope. However, if there were difficulties passing the 
stricture with the introducer of the stent, a dilatation was 
performed up to a maximum of 12 mm. Technical failure 
was defined as inability to place a stent due to technical 
problems during the initial procedure, or any other event 
on day 0 that made further participation impossible. Imme-
diately after stent placement, its position was documented 
with a postero-anterior and lateral chest X-ray. The major-
ity of the patients were examined in the standing position. 
The patients received additional written and oral informa-
tion after receiving the stent. These instructions included 
advice on diet and ingesting only liquid nutrients for the 
first 3 days after the procedure.
Follow-up
The follow-up was scheduled at 1  week, 4  weeks, and 
3 months after the procedure. A chest X-ray was performed 
on each occasion and the patients filled in the dysphagia 
and QoL questionnaires. An independent secondary survey 
of the patient’s medical records at the treating hospital was 
done after a patient’s death to ensure that any stent-related 
events and re-interventions had been recorded.
Variables
Migration was evaluated by measurements on conventional 
frontal and lateral chest X-rays by an experienced consult-
ant thoracic radiologist. The stent position was measured on 
the lateral projection in relation to thoracic structures such 
as the thoracic vertebrae and the aortic arch. All images 
were stored and analyzed on the same work station (Advan-
tage Workstation VolumeShare 5 (AW 4.6), GE Healthcare, 
Waukesha, WI, U.S.A. with Multisync LCD 1990SXI NEC 
monitors) to minimize any procedure-related differences. It 
was decided that a stent displacement of >20  mm would 
be defined as a stent migration. This value was chosen 
in order to avoid over-interpretation of stent movements 
mainly due to two reasons; first, some foreshortening of a 
stent due to its expansion occurs and second, since differ-
ences in the level of inspiration might affect the location of 
the reference anatomical structures within the thoracic cav-
ity. Another rationale was that movements less than 20 mm 
might not be of clinical significance, since each stent was 
routinely placed with a 20 mm overlap.
Fig. 1  Photograph depicting the stents that were examined in this 
study with the proximal endings to the left. A The semi-covered 
 Ultraflex® stent; B the fully covered  Wallflex® stent
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Total dislocation was defined as no stent being vis-
ible in the esophagus at X-ray or at endoscopy. The total 
dislocations were included as a stent migration >20  mm 
event at the subsequent follow-up and were also evaluated 
separately.
Re-interventions the indication for re-interventions was 
patient complaints of sudden or progressive inability to 
swallow regardless of X-ray findings.
Dysphagia was investigated with two well-known instru-
ments, the Watson dysphagia score [20, 21] and the Ogilvie 
score [19, 22], as well as with a symptom-oriented quality 
of life instrument that has a module that captures informa-
tion regarding swallowing difficulties (QLQ-OG25) [23].
Health-related quality of life (QoL) was measured 
with validated instruments originating from the Euro-
pean Organization for Research and Treatment of Cancer 
(EORTC), which has a generic instrument that measures 
global QoL in patients with cancer (QLQ-C30) [24] and 
a more symptom-specific instrument that is developed for 
cancer in the esophagus and stomach (QLQ-OG25) [23]. 
These are well known, validated instruments with the 
added benefit of having normal reference values for the 
healthy population [25, 26].
Statistics
A sample size of 43 patients in each group was calculated 
based on an estimate [11–15] that the expected rate of 
migration in the conventional scSEMS group was 10% and 
in the group with fcSEMS 35%, whereupon a correspond-
ing difference could be detected with a power of 80% and 
a significance level of 95%, (p < 0.05). The SPSS statisti-
cal program was applied for data analysis. The point preva-
lence of data was compared using parametric or non-para-
metric tests where appropriate. A p value of less than 0.05 
was considered statistically significant.
Ethics
This study was performed according to the Declaration of 
Helsinki and the Ethical Review Act. The study protocol 
was approved by the Ethical Review Board Authority in 
Stockholm (protocol 2009/3:7). Written informed consent 
was obtained from each participant before inclusion in the 
trial. The trial is registered in the ClinicalTrials.gov (NCT 
02166320).
Results
Ninety-five patients were included, and 86 patients were 
available for the initial analysis of the primary outcome 
variable at 1 week. Because of the nature of this aggressive 
disease, the number of patients in each group diminished 
for every scheduled follow-up (Fig.  2). At the scheduled 
follow-up at 1 week, 15 out of 95 randomized patients had 
left the study, which means that 80 patients were available 
for the initial analysis of the secondary variables (2 were 
dead; 7 had had technical failure; 6 stents had migrated, 
3 in each group, to an extent that re-intervention was nec-
essary) (Fig. 2). In 2 patients in the fcSEMS group and 3 
patients in the scSEMS group, it was impossible to pass 
the tumor with the guide-wire. Two additional patients 
were excluded on day 0 (1 scSEMS patient suffered a per-
foration requiring surgery and 1 fcSEMS patient did not 
get the allocated stent). These patients were thus denoted 
as technical failures. There were no differences in demo-
graphic background characteristics between the two groups 
(Table 1).
Stent migration
Over a period of 3  months, 6 out of 45 patients (13.3%) 
in the fcSEMS group and 11 out of 43 (25.6%) of the 
patients in the scSEMS group experienced stent migration. 
During the total survival span of the patients, stent migra-
tion occurred in 9 out of 45 (20.0%) of the patients in the 
fcSEMS group compared to 16 out of 43 (37.2%) of the 
patients in the scSEMS group, a difference that was not 
significant (Table 2). In addition, there was no significant 
difference between the groups at any time point with regard 
to the migration distance (Table  2). An interesting obser-
vation was that stent migration occurred not only in the 
distal direction but in the oral direction as well, although 
less frequently (Table 2). In the scSEMS group, 2 patients 
experienced total stent dislocation at 1 week. At 4 weeks, 
no patients, and at 3  months, 1 patient, experienced total 
dislocation in this group. The corresponding figures in the 
fcSEMS group were 1, ,1, and 0.
Dysphagia
Dysphagia measured with three different instruments dis-
played similar outcomes. There was a significant reduction 
of dysphagia for both groups. The data derived with the 
Ogilvie score and with the dysphagia module (QLQ-OG25) 
are suggestive of better dysphagia relief for the fcSEMS 
at 3 months; but these differences did not reach statisti-
cal significance (0.081 and 0.067, respectively) (Table 3). 
Similarly, the differences in the improvement of dysphagia 
measured with the Watson score seemed in favor of the 
fcSEMS stent, but this was not statistically substantiated 
(p = 0.107). There were no differences in any of the scores 
at the 1 week and 4 week observation points (Table 3).
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Fig. 2  Flow chart showing numbers of patients included in each arm 
for evaluation of the primary variable, stent migration. Technical fail-
ures were defined as either impossibility to place a stent, or any other 
event that occurred on the day of inclusion that made further evalua-
tion impossible. New/re-adjusted stent was defined as stent migration 
or dislocation to such an extent that the patient needed a new stent or 




Overall QoL was measured with EORTC QLQ-C30. Both 
groups expectedly reported a similarly low global QoL 
score at randomization. No significant difference in overall 
QoL between the two stent designs was found during fol-
low-up (Table 4).
Survival
Kaplan–Meier analysis with the log-rank test showed no 
significant differences in survival between the groups 
(p = 0.53).
Re-interventions
There were 15 (scSEMS) vs. 8 (fcSEMS) interventions in 
total over the studied 3 months, where it had been deemed 
necessary to perform a new endoscopy due to the patient’s 
complaints or symptoms. Again a tendency toward a lesser 
need for re-interventions was seen in the fcSEMS group 
(p = 0.083) (Table 2). The re-interventions in the scSEMS 
group included the following: 1 patient with a stent dislo-
cation that needed repositioning; 2 patients who needed 
a new stent due to complete dislocation; 5 patients with 
well-placed stents and no endoscopy findings that could 
explain the patient’s complaints; 2 patients with tumor 
in-growth and 5 patients with food impaction. Correspond-
ing numbers in the fcSEMS group were: 3; 3; 2; 0, and 0, 
respectively.
Complications
There was only one serious complication. A patient in the 
scSEMS group experienced a perforation at stent insertion 
on day 0 and received emergency surgery. Other complica-
tions that were minor included bleeding, reflux, and pain 
with no differences between the groups.
Discussion
For patients with inability to swallow due to an advanced 
malignancy of the esophagus and GEJ, it is of critical 
importance to treat the dysphagia and alleviate symp-
toms. From a patient perspective, it is of great importance 
that such treatment is safe and effective, and has few side 
effects, thus minimizing additional interventions. Stent 
placement has the benefits of providing a well-documented 
and rapid onset of the effect and is often accessible close to 
the patient since it can be performed at most local endos-
copy units. One challenge is of course to choose an optimal 
stent type that carries a minimal risk for stent migration 
and other complications.
In this prospective, randomized study, we aimed to 
establish whether modifications of an fcSEMS aimed at 
Table 2  Stent 
migration > 20 mm, migration 
distance in millimeters and 
numbers of endoscopic 
re-interventions
Measured at 1  week, 4 weeks, and 3  months after stent placement. Migration in proximal direction is 
denoted as negative values. The accumulated numbers at 3 months and during the subjects’ life span are 
also shown
Pearson Chi-Square  test1 or two-tailed Mann–Whitney U  test2 was used for data evaluation. p < 0.05 was 
considered significant
scSEMS fcSEMS p value
Stent migration >20 mm number of cases
 At 1 week 4 4 0.9711
 At 1 month 3 1 0.2931
 At 3 months 4 1 0.1541
 Total numbers at 3 months 11 (25.6%) 6 (13.3%) 0.1451
 Total number during survival 16 (37.2%) 9 (20.0%) 0.0681
Migration distance in millimeters
 1 week median (min–max) 2.0 (−20 to 70) 0.0 (−30 to 144) 0.2432
 1 month median (min–max) 5.5 (−39 to 50) 2.5 (−16 to 91) 0.4152
 3 months median (min–max) 10.5 (−11 to 42) 0.0 (−7 to 33) 0.2702
 Proximal migration at one week (n = yes) 8 (24.2%) 13 (36.1%) 0.2311
Numbers of endoscopic re-interventions
 1 week 6 (13.9%) 5 (11.6%) 0.7441
 1 month 5 (15.6%) 2 (6.7%) 0.2881
 3 months 4 (25.0%) 1 (8.3%) 0.3221
 Total interventions at 3 months 15 (34.9%) 8 (18.6%) 0.0831
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maintaining its positioning could be sufficient to reduce 
its tendency to migrate, a phenomenon that often causes 
symptoms and necessitates re-interventions. Given that ear-
lier studies have consistently shown that fcSEMS are more 
likely to dislocate than scSEMS [11–15], we hypothesized 
that this would still be the case despite of the novel design 
modifications undertaken to prevent such migration. We 
found however no difference between the two stent mod-
els with regard to the actual distance of migration or the 
migration frequency. It would appear, then, that the novel 
design modifications of the fcSEMS, i.e., a flare in both 
ends with a modified shape and the lining located at the 
interior side leaving bare mesh on the exterior stent sur-
face, are indeed effective in reducing fully covered stents’ 
tendency to migrate. Interestingly, this was in spite of the 
somewhat lower radial force the  Wallflex® fcSEMS exhib-
its compared to the conventional  Ultraflex® scSEMS used 
here. The finding that the need for endoscopic re-interven-
tions was, if anything, lower in the fcSEMS group, further 
supports the comparable patency of the fcSEMS vs. the 
scSEMS. Our findings are also consistent with a previous 
study on malignant strictures in which the safety and effi-
cacy of the fully covered  Wallflex® stent were investigated 
[27]. In that study, however, individual-based effects before 
and after stent placement were compared with historical 
data, and no randomized control arm was included [27]. 
Regardless of these limitations, the inserting of a fcSEMS 
reduced the risk of recurrent dysphagia due to disloca-
tion, and improved dysphagia scores similar to our find-
ings (Table  3) as well as to earlier descriptive studies on 
scSEMS [11, 16, 17].
In contrast to earlier investigations [8, 9, 11–13, 15–17, 
27–30], we applied a unique but simple method to objec-
tively evaluate stent migration. We used chest X-rays, 
which allows objective measures of the actual stent position 
to be taken directly, permitting quantification of any pos-
sible changes during the follow-up. It may be argued that 
small movements of the SEMS may be of marginal clini-
cal importance, and that perceived symptoms and re-inter-
ventions rather than direct objective measures of migration 
distance should therefore be the preferred primary outcome 
variable. Although it is of vital importance to take into con-
sideration subjective symptoms in clinical palliative care, 
it is well known that patients with advanced cancer of the 
esophagus and GEJ do experience a variety of symptoms 
in general, which may change from day to day [31–33]. As 
it was evident in the present study, these symptoms are not 
necessarily always related to stent migration or dislocation. 
Thus, if re-interventions decided solely by symptoms are 
used as the main study outcome variable and as a proxy for 
migration, it is possible that study patients risk having to 
undergo some unnecessary invasive endoscopic investiga-
tions. Stents as such can also cause symptoms even when 
they remain in the correct position [14], and conversely 
movements of the stents may well be missed unless the 
patient experiences symptom aggravation. Using direct 
X-ray aided measurements in the studies of stent migration, 
Table 3  Dysphagia measured with three different scales.
The two-tailed Mann–Whitney U test was used for data evaluation. 
p < 0.05 was considered significant. Results are presented as median, 
range, and n = numbers of patients per group






































































Table 4  Overall Quality of life measured with QLQ-C30.
Two-tailed Mann–Whitney U test was used for data evaluation. 
p < 0.05 was considered significant. Higher value means better per-
ceived QoL. Quite low values were found initially. A random sample 
of Swedish adults in the same age group has a mean value of 77.5 
(SD 22.0)




41.7 (0.0–91.7) 33.3 (0.00–83.3) 0.212
1 week median (min–
max)
41.7 (0.0–83.3) 25.0 (0.0–66.7) 0.107
1 month median (min–
max)
41.7 (0.0–100.0) 33.3 (0.0–66.7) 0.260
3 months median 
(min–max)
62.5 (8.3–83.3) 41.7 (0.0–75.0) 0.142
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the location of the stent may be determined more objec-
tively and without burdening the patients with additional 
invasive procedures unless needed.
In addition to investigating stent migration and allowing 
for comparisons to be made with earlier studies in which 
symptoms were used as the main outcome variables, we 
evaluated dysphagia, QoL, re-interventions, technical fail-
ures, and survival as secondary variables. As expected, 
individual dysphagia scores were improved in response 
to SEMS placement at all time points. We even noted a 
tendency toward less dysphagia in the fcSEMS group at 
3 months as assessed with the Ogilvie scale and the QLQ-
OG25 scale (Table 3). This may suggest that the fcSEMS 
could be advantageous in providing dysphagia relief in 
patients with a longer life expectancy. It is difficult to firmly 
interpret such a potential effect; a limitation of this study is 
of course that the number of remaining evaluable patients 
was notably very small in both groups at 3 months, due to 
the aggressive nature of the cancer disease. In addition, the 
study was powered with regard to the primary variable, 
and at a group level, no significant difference between the 
specific stent designs was detected at any time point with 
regard to reported dysphagia (Table  4). This latter result 
notwithstanding, our results motivate a future clinical trial 
comparing these stent designs powered for measuring dys-
phagia as the primary outcome variable.
Concerning overall QoL, the scores are concordant 
to what has previously been reported for corresponding 
patient groups [3, 34]. We noted that QoL in fact seemed to 
be unchanged or slightly reduced the first week after SEMS 
treatment (Table 4). This observation is consistent with ear-
lier studies by Shensi et al. and Madhusudhan et al. [35, 36] 
suggesting that a stent may cause some initial symptoms 
that can be negatively perceived such as reflux and pain 
[14]. Over time, there was an improvement in overall QoL 
at three months for both stent types, but with no differences 
between the groups.
In conclusion, this randomized controlled trial shows 
that the fcSEMS used in this study does not migrate more 
compared to the conventional scSEMS and indicates that it 
is at least similar to the conventional scSEMS with regard 
to migration frequency and distance. Whether newer 
fcSEMS may have an advantage in providing better dys-
phagia relief in patients with longer survival expectancy 
needs to be established.
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